Document:

Exhibit 10.10

 

AGREEMENT TO SERVE AS CHIEF DEVELOPMENT OFFICER

 

This Agreement (the “Agreement”)
is entered into as of May 29, 2015 (the “Effective Date”) by and between Tekmira Pharmaceuticals Corp., (the
“Company”), and William T. Symonds (“Executive”).

 

 

 

NOW, THEREFORE, in consideration of the mutual
covenants and agreements contained herein, and with reference to the above recitals, the parties hereby agree as follows:

 

1.                 
Duties and Scope of Responsibilities.

 

(a)               
Positions and Duties. Executive will serve as the Company’s Chief Development Officer, leading the clinical
development strategy of the Company’s portfolio of hepatitis B drug combinations. Executive will render such business and
professional services in the performance of his duties, consistent with Executive’s position within the Company, and as will
reasonably be assigned to him by the Company’s Chief Executive Officer. The period of Executive’s employment under
this Agreement is referred to herein as the “Term.”

 

(b)              
No Conflict. Executive represents and warrants that Executive’s execution of this Agreement and Executive’s
performance of proposed duties under this Agreement shall not violate any obligations Executive may have to any other employer,
person or entity, including any obligations with respect to proprietary or confidential information of any other person or entity.
The Company understands, acknowledges and agrees that (i) Executive is currently, and will continue to be, an employee of
Roivant Sciences, Inc. (“Roivant”) and (ii) the Company and Executive agree that the Executive’s duties
hereunder may not interfere with his employment with and/or services to Roivant and his duties in connection therewith. Roivant
is an intended third-party beneficiary of this Section 1(b).

 

2.                 
Compensation.

 

(a)               
Base Salary. In consideration of the services to be rendered under this Agreement, the Company shall pay Executive
a salary at the rate of One Hundred and Ninety Thousand Dollars ($190,000) per year (the “Base Salary”). The
Base Salary will be paid periodically in accordance with the Company’s normal payroll practices and be subject to the usual,
required withholdings. Executive's Base Salary will be reviewed from time to time in accordance with the established procedures
of the Company for adjusting salaries for similarly situated employees and may be adjusted in the sole discretion of the Company.

 

3.                 
Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by
Executive in the furtherance of or in connection with the performance of Executive’s duties hereunder, in accordance with
the Company’s expense reimbursement policy as in effect from time to time.

 

4.                 
At-Will Employment. The parties agree that Executive’s employment with the Company will be “at-will”
employment and may be terminated at any time with or without cause or notice. Executive understands and agrees that neither his
job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis
for modification, amendment, or extension, by implication or otherwise, of his employment with the Company.

 

    	 

    	 

    

5.                 
Confidential Information. Executive agrees to enter into the At-Will Employment, Confidential Information, Invention
Assignment Agreement (the “Confidential Information Agreement”). Executive’s receipt of any benefits in
connection with or following Executive’s termination will be subject to Executive continuing to comply with the terms of
Confidential Information Agreement.

 

6.                 
Non-Disclosure of Third Party Information. Executive represents and warrants and covenants that Executive shall not
disclose to the Company, or use, or induce the Company to use, any proprietary information or trade secrets of others at any time,
including but not limited to any proprietary information or trade secrets of Roivant Sciences, Inc., or any former employer, if
any; and Executive acknowledges and agrees that any violation of this provision shall be grounds for termination and could subject
Executive to substantial civil liabilities and criminal penalties. Executive further specifically and expressly acknowledges that
no officer or other employee or representative of the Company has requested or instructed Executive to disclose or use any such
third party proprietary information or trade secrets.

 

7.                 
Non-Competition and Non-Solicitation. During the Term, Executive shall not, without the advance written consent of
the Board, such consent to be granted or withheld in the Board’s sole discretion:

 

(a) work or consult, whether directly or indirectly, on
the research, development or commercialization of any treatment for hepatitis B virus infection in humans with any entity other
than the Company;

 

(b) directly or indirectly, on his own behalf or on behalf
of any other person, firm, partnership, corporation or other entity, (i) solicit for employment, interfere with or attempt to entice
away from the Company or any of its subsidiaries, any individual who either (x) is employed by the Company or any of its subsidiaries
at the time of such solicitation, interference or enticement, or (y) has been so employed within three (3) months prior to such
solicitation, interference or enticement, or (ii) solicit, divert, call on, induce or otherwise harm the Company’s relationship,
or attempt to solicit, divert, call on, induce, or otherwise harm the Company’s relationship, with any person which has had
at any time during the term of this Agreement a business relationship with the Company or its affiliates, including without limitation,
a sales representative, supplier, lender, borrower, guarantor, landlord, tenant, lessor, lessee, but excluding employees.

 

8.                 
Assignment. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives
of Executive upon Executive’s death and (b) any successor of the Company. Any such successor of the Company will be deemed
substituted for the Company under the terms of this Agreement for all purposes. For this purpose, “successor”
means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly
or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive
any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent
and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive’s right to compensation
or other benefits will be null and void.

 

    	 

    	 

    

9.                 
Severability. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision.

 

10.             
Integration. This Agreement, together with the Confidential Information Agreement and the Plan, represents the entire
agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements
whether written or oral. This Agreement may be modified only by agreement of the parties by a written instrument executed by the
parties that is designated as an amendment to this Agreement.

 

11.             
Waiver of Breach. The waiver of a breach of any term or provision of this Agreement, which must be in writing, will
not operate as or be construed to be a waiver of any other previous or subsequent breach of this Agreement.

 

12.             
Headings. All captions and section headings used in this Agreement are for convenient reference only and do not form
a part of this Agreement.

 

13.             
Tax Withholding. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.

 

14.             
Governing Law. This Agreement will be governed by the laws of the Commonwealth of Pennsylvania without regard to
its conflict of laws provisions.

 

15.             
Acknowledgment. Executive acknowledges that he has had the opportunity to discuss this matter with and obtain advice
from his private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this
Agreement, and is knowingly and voluntarily entering into this Agreement.

 

16.             
Counterparts. This Agreement may be executed in counterparts, and each counterpart will have the same force and effect
as an original and will constitute an effective, binding agreement on the part of each of the undersigned.

 

IN WITNESS WHEREOF, each of the parties has
executed this Agreement, in the case of the Company by their duly authorized officers, as of the day and year first above written.

 

 

 

 

 

[Signature page follows]

 

 

 

 

    	 

    	 

    

COMPANY:

 

 

	TEKMIRA PHARMACEUTICALS CORP.  	 
	
        By:  /s/ Mark Murray                                               

        Its: Chief Executive Officer                                    

         
	Date:  _________________________________

	 	 
	EXECUTIVE:	 
	/s/ William T. Symonds__________________	Date:  _________________________________
	William T. SymondsExhibit 10.11

 

EXECUTIVE
EMPLOYMENT AGREEMENT

 

THIS AGREEMENT made this 4
day of August, 2015

 

BETWEEN:

 

ARBUTUS BIOPHARMA CORPORATION, a company
incorporated under the laws of British Columbia (the “Company”), with offices at 100 – 8900 Glenlyon
Parkway, Burnaby, British Columbia fax: (604) 419-3201

 

AND:

 

Bruce Cousins (the “Executive”),
of Victoria, British Columbia, Canada

 

WHEREAS:

 

A.   The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals;

 

B.    The Executive has the
expertise, qualifications and required certifications to perform the services contemplated by this Agreement; and

 

C.    The Company wishes to employ the Executive to perform the
services, on the terms and conditions herein set forth, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged.

 

NOW THEREFORE THIS AGREEMENT WITNESSES that the parties hereto agree
as follows:

 

 

1.             EMPLOYMENT

 

		(a)	The Executive will be employed by and will serve the Company as its Chief Financial Officer
and will have powers and duties consistent with such position as may from time to time be prescribed by the Chief Executive Officer
of the Company. The Executive will report directly to the Chief Executive Officer of the Company and will perform the duties
and responsibilities assigned to the Executive from time to time by the Chief Executive Officer. The Executive will comply with
all lawful instructions given by the Chief Executive Officer of the Company.

 

     

     

    

 

		(b)	The terms and conditions of this Agreement will have effect as and from 4 day of
August, 2015 and the Executive’s employment as Chief Financial Officer will continue until terminated as provided
for in this Agreement.

 

		(c)	The Executive acknowledges and agrees that in addition to the terms and conditions of this Agreement,
the Executive’s employment with the Company is subject to and governed by the Company’s policies as established from
time to time. The Executive agrees to comply with the terms of such policies so long as they are not inconsistent with any provisions
of the Agreement. The Executive will inform himself of the details of such policies and amendments thereto established from time
to time.

 

		(d)	The Executive will devote himself exclusively to the Company’s business and will not be employed
or engaged in any capacity in any other business without the prior permission of the Company, such permission not to be unreasonably
withheld. Notwithstanding the foregoing, the Executive may manage his personal investments or engage charitable or other community
activities as long as those services and activities do not interfere with the Executive’s performance of his duties to the
Company.

 

		(e)	Concurrently with the execution and delivery of this Agreement and in consideration of the Executive’s
employment by the Company, the Executive and the Company will enter into a “Confidentiality and Assignment of Inventions
Agreement” in the form attached hereto as Exhibit A.

 

2.             REMUNERATION AND BENEFITS

 

		(a)	Base Salary. The Company will pay the Executive an annual salary of US$350,000, less required
deductions (the “Base Salary”). The Base Salary will be payable semi-monthly. The Executive’s Base Salary
will be reviewed annually by the Chief Executive Officer of the Company and is subject to increase but not decrease, except for
an across-the-board salary reduction affecting all or substantially all senior executives of the Company, nor will it necessarily
result in an increase to the Base Salary. The base salary in effect at any given time is referred to as “Base Salary”
and this Agreement need not be modified to reflect a change in Base Salary. The Base Salary is subject to withholding and payable
in a manner that is consistent with the Company’s usual payroll practices for senior executives.

 

		(b)	Bonus. The Executive is eligible to be considered for an annual discretionary bonus of up
to 40 percent of Base Salary (such bonus, the “Target Bonus”); which will be subject to the terms of the bonus
plan and approval of the Company’s Board of Directors (the “Board”), in its sole discretion, on an annual
basis. Any bonus payable during the first year of the Executive’s employment will be pro-rated. Payment of a bonus in any
one year will not indicate the payment of a bonus in any other year.

 

     -2-

     

    

 

 

		(c)	Expenses. The Company will reimburse the Executive for all reasonable expenses actually
and properly incurred by the Executive in performing services under this Agreement, in accordance with the policies and procedures
then in effect and established by the Company for its senior executives. The Executive will provide the Company with receipts supporting
the Executive’s claims for reimbursement.

 

		(d)	Other Benefits. The Company will facilitate the Executive’s enrolment in the Company’s
insurance benefits plans, as amended from time to time by the Company or the insurance carrier. In all cases, eligibility to participate
in the plans and to receive benefits under the plans will be subject to the terms and requirements of the applicable insurance
carrier in accordance with the formal benefits plan documents and policies. Any issues with respect to entitlement to or payment
of benefits under the benefits package will be governed by the terms of such documents and policies. The Company is not responsible
for the payment of benefits in any circumstance. Further, the Company reserves the right, in its sole discretion, to change any
of the insurance benefit plans or providers, however, if the Company is unable to maintain similar coverage as to the insurance
benefits plans or the providers, then the Executive will be provided with compensation to assist in securing the Executive’s
own coverage, such compensation to be determined by the Company.

 

		(e)	Equity Compensation. Subject to the discretionary approval of the Company’s Board
of Directors, and in accordance with the Company’s annual performance and compensation review process, the Executive shall
be eligible to receive equity awards under the  Arbutus Biopharma Corporation Share Incentive Plan and or any other similar
equity incentive plan to the same extent as other executives of the Company.

 

		(f)	Vacation. The Executive is entitled to paid holidays and vacation days each year, in an
amount determined in accordance with and subject to the Company’s applicable policies in effect, and as may be amended from
time to time. The Executive will be entitled to 25 days of vacation per calendar year, which will be pro-rated for any year in
which the Executive is only employed with the Company for a portion of the year or for any period in which the Executive is not
a full-time employee. Vacation days will be scheduled at times that are mutually acceptable to the Executive and the Company. Carry-over
of vacation days will be according to Company policy, and any accrued but unused vacation days will be paid out upon termination.

 

3.             NON-COMPETITION AND NON-SOLICITATION

 

		(a)	The biotechnology industry is highly competitive and employees leaving the employ of the Company
have the ability to cause significant damage to the Company’s interests if they join a competing business immediately upon
leaving the Company.

 

     -3-

     

    

 

(b)              
Definitions:

 

(i)                 “Affiliate”
means, in respect of the Company, a company or other entity which directly or indirectly controls, is controlled by, or is
under common control with, the Company. For the purposes of this definition, “control” means direct or indirect
beneficial ownership of a greater than 50% interest in the income of such company or entity or such other relationship as, in
fact, constitutes actual control. For greater certainty, without limiting the generality of the foregoing, Protiva
Biotherapeutics Inc., Protiva Biotherapeutics (USA) Inc. and Arbutus Biopharma, Inc. are Affiliates of the Company.

 

(ii)           
“Business” or “Business of the Company” means:

 

(A)          researching, developing, producing and marketing any treatment for hepatitis B virus infection in humans; or

 

(B)           any
other treatment area in which the Company has an active research and development program on the date this Agreement terminates
and in connection with which the Executive directly provided service or had direct supervisory responsibilities.

 

(iii)           “Competing Business” means any endeavour, activity or business which is competitive in any material way
with the Business of the Company worldwide.

 

(iv)           “Contact”
means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder, investor, collaborator,
strategic partner, licensee, contact or prospect of the Company (or of its partners, funders or Affiliates) with whom the Executive
dealt or otherwise became aware of during the term of the Executive’s employment in any capacity with the Company.

 

		(v)	“Restricted Period” means:

 

(A)        
in the event that the Executive is terminated pursuant to Section 5(d) of this Employment Agreement, a period equivalent
to the amount of notice that the Executive is entitled pursuant to Section 6(b)(i); or

 

(B)         
in the event that the Executive’s employment is terminated pursuant to a Change of Control (as defined below), a period
equivalent to the amount of notice that the Executive is entitled pursuant to Section 7(d)(iii)(A).

 

		(c)	Reasonableness. The Executive hereby acknowledges and agrees that:

 

		(i)	both before and since the commencement of the Executive’s employment by the Company, the Company
has operated and competed and will operate and compete worldwide, with respect to the Business of the Company;

 

    -4- 

     

    

 

		(ii)	competitors of the Company and the Business are located worldwide;

 

		(iii)	in order to protect the Company adequately, any enjoinder of competition would have to apply to any
country in which the Company, during the term of the Executive’s employment, had material business relationships;

 

		(iv)	during the course of the Executive’s employment with the Company, on behalf of the Company,
the Executive will acquire knowledge of, and will come into contact with, initiate and establish relationships with, both existing
and new clients, customers, suppliers, principals, contacts and prospects of the Company, and that in some circumstances the Executive
may become the senior or sole representative of the Company dealing with such persons; and

 

		(v)	in light of the foregoing, the provisions of this Section 3 are reasonable and necessary for the proper
protection of the Business of the Company.

 

		(d)	Restrictive Covenant. Except as set forth on Exhibit C attached hereto, during the term
of the Executive’s employment and for the Restricted Period after the termination thereof, the Executive shall not, without
the prior written consent of the Board, such consent to be granted or withheld in the Board’s sole discretion, within the
geographic scope of any country in which the Company, during the term of the Executive’s employment, had material business
relationships, carry on or be employed by or engaged in or have any financial or other interest in or be otherwise commercially
involved in a Competing Business, directly or indirectly, either individually or in partnership or jointly or in conjunction with
any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner
whatsoever.

 

		(e)	Exception. The Executive shall not be in default of Section 3(d) by virtue of the Executive:

 

		(i)	following the termination of employment, holding, strictly for portfolio purposes and as a passive
investor, no more than five percent (5%) of the issued and outstanding shares of, or any other interest in, any corporation or
other entity which is listed on any recognized stock exchange, that is a Competing Business; or

 

		(ii)	during the term of the Executive’s employment, holding, strictly for portfolio purposes and
as a passive investor, issued and outstanding shares of, or any other interest in, any corporation or other entity, the business
of which corporation or other entity is in the same Business as the Company provided such corporation is not a Competing Business,
and provided further that the Executive first obtains the Company’s written consent, which consent will not be unreasonably
withheld.

 

If the Executive holds issued and outstanding shares or
any other interest in a corporation or other entity pursuant to Section 3(e)(ii) above, and following the acquisition of such shares
or other interest the business of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose
of the Executive’s shares or other interest in such corporation or other entity.

 

    -5- 

     

    

 

		(f)	Non-Solicitation. The Executive shall not, during the term of the Executive’s employment
and for the Restricted Period after the termination thereof for any reason, whether legal or illegal, either individually or in
partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor,
employee, shareholder or in any manner whatsoever, without the prior written and informed consent of the Company, directly or indirectly:

 

		(i)	canvass or solicit the business of (or procure or assist the canvassing or soliciting of the business
of) any Contact, or otherwise solicit, induce or encourage any Contact to curtail or cease its relationship with the Company, for
any purpose which is competitive with the Business; or

 

		(ii)	accept (or procure or assist the acceptance of) any business from any Contact which business is competitive
with the Business; or

 

		(iii)	be employed by or supply (or procure or assist the supply of) any goods or services to any Contact
for any purpose which is competitive with the Business; or

 

		(iv)	employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise
entice away from or solicit, induce or encourage to leave the employment or engagement of the Company, any individual who is employed
or engaged by the Company whether or not such individual would commit any breach of the Executive’s contract or terms of
employment or engagement by leaving the employ or the engagement of the Company, provided that the Executive shall be permitted,
solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.

 

(g)           Validity. The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive’s
activities following the termination of the Executive’s employment with the Company be restricted in the manner described
in this Section 3, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions.
The Executive agrees that should any of the restrictions contained in this Section 3 be found to be unreasonable to any extent
by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of the restriction,
the area of the restriction or the duration of the restriction, then such restriction shall be reduced to that which is in fact
declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration, in order
to ensure that the intention of the parties is given the greatest possible effect.

 

    -6- 

     

    

 

4.             INJUNCTIVE
RELIEF

 

		(a)	The Executive understands and agrees that the Company has a material interest in preserving the
relationships it has developed with its executives, customers and suppliers against impairment by competitive activities of a former
executive. Accordingly, the Executive agrees that the restrictions and covenants contained in Section 3 are reasonably required
for the protection of the Company and its goodwill and that the Executive’s agreement to those restrictions and covenants
by the execution of this Agreement, are of the essence to this Agreement and constitute a material inducement to the Company to
enter into this Agreement and to employ the Executive, and that the Company would not enter into this Agreement absent such an
inducement.

 

		(b)	The Executive understands and acknowledges that if the Executive breaches Section 3, that breach
will give rise to irreparable injury to the Company for which damages are an inadequate remedy, and the Company may pursue injunctive
relief for such breach in a court of competent jurisdiction.

 

5.             TERMINATION

 

The Executive’s employment by the Company may be terminated
under the following circumstances:

 

		(a)	Death. The Executive’s employment hereunder will terminate upon the Executive’s
death.

 

		(b)	Disability. The Company may terminate the Executive’s employment if the Executive
is disabled (as determined by the Chief Executive Officer) by a condition that qualifies Executive for long term disability benefits
under the Company’s then-current long term disability plan, in a manner that renders the Executive unable to perform the
essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable
accommodation for a period of six (6) months or more. Nothing in this Section 5(b) will be construed to waive the Executive’s
rights, if any, under the Company’s insurance benefits plans accruing prior to termination or under applicable law.

 

		(c)	Termination by Company for Cause.

 

		(i)	The Company may terminate the Executive’s employment For Cause at any time, without notice
or payment in lieu thereof. The payment by the Company of the Executive’s Accrued Benefits shall be subject to any other
rights or remedies of the Company under law and thereafter all obligations of the Company under this Agreement shall cease.

 

		(ii)	For the purposes of this Agreement, “For Cause” shall mean:

 

		(A)	the Executive commits a crime involving dishonesty, breach of trust, or physical harm to any person
(excluding driving while affected by drugs or alcohol) or any violation of provincial, state or federal securities laws;

 

    -7- 

     

    

 

		(B)	the Executive willfully engages in conduct that is in bad faith and materially injurious to the
Company or its Affiliates, monetarily or otherwise, including but not limited to, misappropriation of trade secrets, fraud or embezzlement;

 

		(C)	the Executive commits a material breach of this Agreement;

 

		(D)	the Executive willfully refuses to implement or follow a lawful policy or directive of the Company;
or

 

		(E)	the Executive willfully and on a continuing basis fails to perform his duties hereunder diligently
and professionally.

 

		(d)	Termination by the Company without Cause.

 

		(i)	The Company, in its sole discretion, may terminate the Executive’s employment under this
Agreement without Cause at any time.

 

		(ii)	For the purposes of this Agreement, any termination by the Company of the Executive’s employment
under this Agreement that does not constitute a termination “For Cause” under Section 5(c) and does not result from
the death or disability of the Executive under Sections 5(a) or 5(b), respectively, shall be a termination “without Cause”.

 

		(e)	Resignation by Executive.

 

		(i)	The Executive may terminate his employment by providing to the Company Notice of Termination of
his employment at least three (3) months prior to the effective date of resignation. During such notice period Executive shall
continue to diligently perform all of Executive’s duties hereunder, provided that the Company shall have the option, in its
sole discretion, to waive such notice period, in whole or in part, and if it does so, the Executive’s resignation will become
effective and the Executive’s employment will cease on the date set by the Company in the notice of waiver, and the Executive
shall be entitled to his Accrued Benefits up to and including the Date of Termination (as defined in Section 5(g)(iii)). In
the event the Company waives the Executive’s notice hereunder, the Company, in its sole discretion, in the circumstances,
may pay the Base Salary portion of the Executive’s Accrued Benefits by way of one or more lump sum payments, by way of salary
continuance or by a combination of both.

 

		(ii)	The Executive may terminate his employment for Good Reason within 12 months following a Change
in Control of the Company in accordance with, and subject to, the process set out in Section 7(c).

 

    -8- 

     

    

 

		(f)	Notice of Termination. Except for termination as specified in Section 5(a), any termination
of the Executive’s employment by the Company or any termination of the Executive’s employment by the Executive must
be communicated by written Notice of Termination to the other party. For the purposes of this Agreement, “Notice of Termination”
means a written notice that indicates the specific termination provision in this Agreement upon which the termination is based.

 

		(g)	Date of Termination. For the purposes of this Agreement, “Date of Termination”
means:

 

		(i)	if the Executive’s employment is terminated by his death, the date of his death;

 

		(ii)	if the Executive’s employment is terminated on account of disability under Section 5(b) or
by the Company for Cause under Section 5(c), or by the Company without Cause under Section 5(d) on the date the Notice of Termination
is given;

 

		(iii)	if the Executive terminates his employment under Section 5(e)(i) without Good Reason, on the effective
date of resignation specified by the Executive in the Notice of Termination (which shall be at least three (3) months after the
date of the Notice of Termination) or, if no such date is specified or if the Company waives the notice period, the date that is
three (3) months after the date of the Notice of Termination; and

 

		(iv)	if the Executive terminates his employment under Section 5(e)(ii) for Good Reason following a Change
in Control of the Company, the date on which a Notice of Termination is given after the end of the Cure Period.

 

Notwithstanding the foregoing, if the Executive gives a
Notice of Termination to the Company that takes effect at a future date, the Company may unilaterally accelerate the Date of Termination
and that acceleration will not be deemed a termination by the Company for purposes of this Agreement.

 

6.             COMPENSATION
UPON TERMINATION

 

		(a)	Termination Generally. If the Executive’s employment with the Company is terminated
for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) on or before
the time required by law, but in no event more than 30 days after the Executive’s Date of Termination:

 

		(i)	unpaid expense reimbursements;

 

		(ii)	accrued but unused vacation to the extent payment is required by law or Company policy;

 

		(iii)	any vested benefits the Executive may have under any employee benefit plan of the Company;

 

    -9- 

     

    

 

		(iv)	any earned but unpaid Base Salary; and

 

		(v)	any earned but unpaid annual bonus for the prior fiscal year;

 

for service up to and including the Date of Termination
(collectively the “Accrued Benefits”). The Executive shall not be entitled to any other salary, compensation,
bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically provided in this Agreement,
under the Company’s employee benefit plans or as expressly required by applicable law.

 

		(b)	Termination by the Company without Cause. If the Executive’s employment is terminated
by the Company without Cause, then the Company shall pay the Executive his Accrued Benefits as of the Date of Termination. In addition,
subject to Section 7 and the Executive providing the Company with a fully effective general release of claims in a form and manner
satisfactory to the Company that includes but is not limited to the terms set forth in the attached Exhibit B (the “Release”)
within the 60-day period following the Date of Termination (and which shall be countersigned by the Company in respect of the non-disparagement
clause therein), the Company shall pay the Executive an amount (the “Severance Amount” calculated as follows:

 

		(i)	an amount equal to eighteen (18) months’ Base Salary, less withholding; plus

 

		(ii)	a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus

 

		(iii)	provided that the Executive is enrolled in the Company’s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company’s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:

 

		(A)	a period of up to 24 months from the Date of Termination, or

 

		(B)	until the Executive becomes eligible to receive health insurance benefits under any other employer’s
group health plan,

 

or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.

 

The Company shall pay the Severance Amount within 60 days
after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company shall make the
payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances, may pay
the Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination of both. The Severance
Amount is inclusive of any entitlement to minimum standard severance under the British Columbia Employment Standards Act.

 

    -10- 

     

    

 

7.             CHANGE
IN CONTROL

 

		(a)	The provisions of this Section 7 set forth the Executive’s rights and obligations upon the
occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive’s
continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any
Change in Control. Where the provisions of this Section 7 apply, they shall supersede the payment of the Severance Amount under
Section 6(b). The provisions of this Section 7 are subject to the Executive providing to the Company, and not revoking, a fully
effective Release.

 

		(b)	Definitions. For purposes of this Agreement:

 

		(i)	“Change in Control” means the consummation of any of the following:

 

		(A)	the sale of all or substantially all of the assets of the Company to an unrelated person or entity;

 

		(B)	a merger, reorganization, or consolidation involving the Company in which the shares of voting
stock outstanding immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving
or resulting entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power
of the surviving or resulting entity;

 

		(C)	the acquisition of all or a majority of the outstanding voting stock of the Company in a single
transaction or a series of related transactions by a person or group of persons; or

 

		(D)	any other acquisition of the business of the Company, as determined by the Board;

 

but any public offering by the Company, or another capital
raising event, or a merger effected solely to change the Company’s domicile does not constitute a Change in Control; and

 

		(ii)	“Good Reason” shall mean the occurrence of any of the following events without
the Executive's prior written consent:

 

		(A)	a change in the Executive’s position which materially reduces the Executive’s responsibilities
from the responsibilities in effect immediately prior to the Change of Control;

 

		(B)	a reduction by the Company of the Executive’s Base Salary or Target Bonus percentage, except
for an across-the-board salary reduction affecting all senior executives of the Company; or

 

    -11- 

     

    

 

 

		(C)	a relocation of Executive’s principal place of employment by more than 80 kilometres.

 

		(c)	Resignation for Good Reason. If the Executive desires to terminate his employment for Good
Reason within 12 months following a Change in Control, the Executive must comply with, and shall be subject to, the following terms
and conditions:

 

		(i)	the Executive reasonably determines in good faith that a Good Reason condition has occurred within
12 months following a Change in Control;

 

		(ii)	the Executive notifies the Company in writing of the first occurrence of the Good Reason condition
within 30 days of the first occurrence of such condition;

 

		(iii)	the Executive cooperates in good faith with the Company’s efforts, for a period of not less
than 30 days following that notice (the “Cure Period”) to remedy the condition;

 

		(iv)	notwithstanding the Company’s efforts, the Good Reason condition continues to exist; and

 

		(v)	the Executive provides to the Company Notice of Termination of his employment within 30 days after
the end of the Cure Period.

 

If the Company cures the Good Reason condition during the
Cure Period, the Good Reason condition is deemed not to have occurred and the Executive may not terminate his employment in respect
of such condition.

 

		(d)	Change in Control Severance. If within 12 months following a Change in Control:

 

		(i)	the Company terminates the Executive’s employment with the Company without Cause; or

 

		(ii)	the Executive resigns from his employment with the Company for Good Reason;

 

then,

 

		(iii)	in addition to paying the Executive his Accrued Benefits and in lieu of paying the Executive the
Severance Amount, the Company shall pay to the Executive an amount (the “Change in Control Severance Amount”)
as follows:

 

		(A)	an amount equal to twenty-four (24) months’ Base Salary, less withholding; plus

 

    -12- 

     

    

 

		(B)	a bonus payment equal to the average of the actual bonus payments, if any, made to the Executive
from the previous three (3) calendar years preceding the Date of Termination, pro-rated for the then current calendar year up to
and including the Date of Termination; plus

 

		(C)	provided that the Executive is enrolled in the Company’s insurance benefits plans pursuant
to Section 2(d), for continuation of coverage under the Company’s insurance benefits plans that the Executive and his dependents
are eligible to receive for the earlier of:

 

		(1)	a period of up to 24 months from the Date of Termination, or

 

		(2)	until the Executive becomes eligible to receive health insurance benefits under any other employer’s
group health plan,

 

or reimburse the Executive for premiums paid by the Executive,
if any, for continuation of coverage under equivalent private coverage.

 

The Company shall pay the Change in Control Severance
Amount within 60 days after the Date of Termination, provided that if that 60-day period extends over two calendar years, the Company
shall make the payment in the second calendar year, and further provided that the Company, in its sole discretion, in the circumstances,
may pay the Change in Control Severance Amount by way of one or more lump sum payments, by way of salary continuance or by a combination
of both. The Change in Control Severance Amount is inclusive of any entitlement to minimum standard severance under the British
Columbia Employment Standards Act; and

 

		(iv)	notwithstanding anything to the contrary in any applicable option agreement or stock-based award
agreement, all stock options and other stock-based awards held by the Executive shall immediately accelerate, vest, and become
fully exercisable or non-forfeitable as of the Date of Termination.

 

8.              RETURN OF MATERIALS UPON TERMINATION OF EMPLOYMENT

 

The Executive will return to the Company all Company documents,
files, manuals, books, software, equipment, keys, equipment, identification or credit cards, and all other property belonging to
Company upon the termination of the executive’s employment with the Company for any reason.

 

    -13- 

     

    

 

9.              
GENERAL PROVISIONS

 

		(a)	Withholding. All payments made by the Company to the Executive
under this Agreement will be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing
in this Agreement is to be construed to obligate the Company to design or implement any compensation arrangement in a way that
minimizes tax consequences for the Executive.

 

		(b)	Successor to Company. The Company shall require any successor (whether direct or indirect,
by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company expressly
to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession
had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession
is a material breach of this Agreement.

 

		(c)	Successor to the Executive. This Agreement inures to the benefit of and is enforceable by
the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees, and legatees. If the
Executive dies after his termination of employment but prior to the completion by the Company of all payments due to him under
this Agreement, the Company shall continue the payments to the Executive’s beneficiary designated in writing to the Company
prior to his death (or to his estate, if the Executive fails to make such a designation).

 

		(d)	Non-Waiver. Failure on the part of either party to complain of any act or failure
to act of the other of them or to declare the other party in default of this Agreement, irrespective of how long such failure continues,
will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default.

 

		(e)	Severability. In the event that any provision or part of this Agreement is determined
to be void or unenforceable in whole or in part, the remaining provisions, or parts thereof, will be and remain in full force and
effect.

 

		(f)	Entire Agreement. This Agreement constitutes the entire agreement between the parties
with respect to the employment of the Executive and supersedes any and all agreements, understandings, warranties or representations
of any kind, written or oral, express or implied, including any relating to the nature of the position or its duration, and each
of the parties releases and forever discharges the other of and from all manner of actions, causes of action, claim or demands
whatsoever under or in respect of any agreement.

 

		(g)	Survival. The provisions of this Agreement survive the termination of this Agreement
and/or the termination of the Executive’s employment to the extent necessary to effectuate the intent of the Parties as expressed
in this Agreement.

 

    -14- 

     

    

 

		(h)	Modification of Agreement. Any modification of this Agreement must be in writing
and signed by both the Company and the Executive or it will have no effect and will be void.

 

		(i)	Disputes. Except for disputes arising in respect of Section 3, all disputes arising
out of or in connection with this Agreement and the employment relationship between the parties, are to be referred to and finally
resolved by arbitration administered by the British Columbia International Commercial Arbitration Centre, pursuant to its Rules.
The place of arbitration will be Vancouver, British Columbia.

 

		(j)	Governing Law. This Agreement will be governed by and construed according to the
laws of the Province of British Columbia, Canada.

 

		(k)	Notices. Any notices, requests, demands, and other communications provided for by this Agreement
are sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered
or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing
with the Company or, in the case of the Company, at its main offices, attention to the Corporate Secretary.

 

		(l)	Independent Legal Advice. The Executive agrees that the contents, terms and effect
of this Agreement have been explained to the Executive by a lawyer and are fully understood. The Executive further agrees that
the consideration described aforesaid is accepted voluntarily for the purpose of employment with the Company under the terms and
conditions described above.

 

    -15- 

     

    

 

		(m)	Counterparts. This Agreement may be executed in any number of counterparts, and by each
party on separate counterparts, each of which counterparts, when so executed and delivered is to be taken to be an original; but
those counterparts together constitute one and the same document. PDF, facsimile, scanned, and electronic signatures have the same
legal effect as original ink signatures.

 

 

IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.

 

 

	
         

        SIGNED, SEALED AND DELIVERED

        by Bruce Cousins in
        the presence of:

         
	
         

        )

        )

        )

        )

        )
	/s/ Bruce Cousins	 
	Witness	
        )

        )
	Bruce Cousins	 
	Address	
        )

        )
	 	 
	 	
        )

        )
	 	 
	 	)	 	 
	Occupation	 	 	 

 

 

ARBUTUS BIOPHARMA CORPORATION

 

	Per:	/s/ Mark J. Murray	 
	 	Mark J. Murray	 

 

 

    -16- 

     

    

 

EXHIBIT A

 

CONFIDENTIALITY

AND ASSIGNMENT OF INVENTIONS AGREEMENT

 

THIS AGREEMENT (this “Agreement”)
dated for reference the 4 day of August, 2015.

 

BETWEEN:

 

ARBUTUS BIOPHARMA CORPORATION

(the “Company”), a company incorporated under the laws of British Columbia with offices at 100 – 8900
Glenlyon Parkway, Burnaby, British Columbia fax: (604) 419-3201

 

AND:

 

Bruce Cousins (the “Executive”),
of Victoria, British Columbia, Canada

 

WHEREAS:

 

A.      The Company is in the business of acquiring, inventing, developing,
discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals; and

 

B.      In connection with the
employment of the Executive by the Company, the parties desire to establish the terms and conditions under which the Executive
will (i) receive from and disclose to the Company proprietary and confidential information; (ii) agree to keep the information
confidential, to protect it from disclosure and to use it only in accordance with the terms of this Agreement; and (iii) assign
to the Company all rights, including any ownership interest which may arise in all inventions and intellectual property developed
or disclosed by the Executive over the course of his work during his employment with the Company, as set out in this Agreement.

 

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of
the employment of the Executive by the Company and the payment by the Company to the Executive of the sum of $10.00 and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.                            INTERPRETATION

 

1.1                           Definitions. In this Agreement:

 

		(a)	“Affiliate” means, in respect of the Company, a company or other entity
                                                               which directly or indirectly controls, is controlled by, or is under common control with, the Company. For the purposes of
                                                               this definition, “control” means direct or indirect beneficial ownership of a greater than 50% interest in
                                                               the income of such company or entity or such other relationship as, in fact, constitutes actual control. For greater
                                                               certainty, without limiting the generality of the foregoing, Protiva Biotherapeutics Inc., Protiva Biotherapeutics (USA) Inc.
                                                               and  Arbutus Biopharma, Inc. are Affiliates of the Company.

 

    

     

    

 

 

		(b)	“Business” or “Business of the Company” means:

 

		(i)	researching, developing, producing and marketing any treatment for hepatitis B virus infection
in humans; or

 

		(ii)	any other treatment area in which the Company has an active research and development program on
the date the Executive’s employment with the Company terminates and in connection with which the Executive directly provided
service or had direct supervisory responsibilities.

 

		(c)	“Confidential Information” shall mean all information, knowledge, or data, whether
in written, oral, electronic or other form, relating to the Business of the Company, whether or not conceived, originated, discovered
or developed in whole or in part by the Executive, that is not generally known to the public or to other persons who are not bound
by obligations of confidentiality and:

 

		(i)	from which the Company or its Affiliates derive economic value, actual or potential, from the information
not being generally known; or

 

		(ii)	in respect of which the Company or its Affiliates otherwise have a legitimate interest in maintaining
secrecy;

 

and which, without limiting the generality of the foregoing,
shall include:

 

		(iii)	all proprietary information licensed to, acquired, used or developed by the Company and its Affiliates
in its research and development activities (including but not restricted to the research and development of RNA interference drugs
and delivery technology), other scientific strategies and concepts, designs, know-how, information, material, formulas, processes,
research data and proprietary rights in the nature of copyrights, patents, trademarks, licenses and industrial designs;

 

		(iv)	all information relating to the Business of the Company, and to all other aspects of the structure,
personnel and operations of the Company and its Affiliates, including financial, clinical, regulatory, marketing, advertising and
commercial information and strategies, customer lists, compilations, agreements and contractual records and correspondence; programs,
devices, concepts, inventions, designs, methods, processes, data, know-how, unique combinations of separate items that is not generally
known and items provided or disclosed to the Company or its Affiliates by third parties subject to restrictions on use or disclosure;

 

 

    2

     

    

 

		(v)	all know-how relating to the Business of the Company, including all biological, chemical, pharmacological,
toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information,
and all applications, registrations, licenses, authorizations, approvals and correspondence submitted to regulatory authorities;

 

		(vi)	all information relating to the businesses of competitors of the Company or its Affiliates, including
information relating to competitors’ research and development, intellectual property, operations, financial, clinical, regulatory,
marketing, advertising and commercial strategies, that is not generally known;

 

		(vii)	all information provided to the Company or its Affiliates by their agents, consultants, lawyers,
contractors, licensors or licensees and relating to the Business of the Company; and

 

		(viii)	all information relating to the Executive’s compensation and benefits, including his salary,
vacation, stock options, rights to continuing education, perquisites, severance notice, rights on termination and all other compensation
and benefits, except that he shall be entitled to disclose such information to his bankers, advisors, agents, consultants and other
third parties who have a duty of confidence to him and who have a need to know such information in order to provide advice, products
or services to him.

 

All Work Product shall be deemed to be the Company’s
Confidential Information.

 

		(d)	“Effective Date” means the 4 day of August, 2015 being the date that the
                                                               Executive started working at the Company, as indicated in his employment agreement with the Company.

 

		(e)	“Intellectual Property” is used in its broadest sense and means and includes
any statutory, common law, equitable, contractual or proprietary rights or interests, recognized currently or in future, in and
to any Inventions, including, without limitation, rights and interests in and to the following:

 

		(i)	knowledge, know-how and its embodiments, including trade secret information;

 

		(ii)	patents in inventions, and all applications therefor;

 

		(iii)	copyrights in artistic, literary, dramatic, musical, and neighbouring works, copyrightable works
of authorship including technical descriptions for products, user guides, illustrations, advertising materials, computer programs,
source code and object code, and all applications therefor;

 

    3

     

    

 

		(iv)	trademarks, service marks, tradenames, business names and domain names and all applications therefor;

 

		(v)	industrial designs and all other industrial or intellectual property and all applications therefor;
and

 

		(vi)	all goodwill connected with the foregoing.

 

		(f)	“Inventions” shall mean any and all inventions, discoveries, developments, enhancements,
improvements, concepts, formulas, designs, processes, ideas, writings and other works, whether or not reduced to practice, and
whether or not protectable under patent, copyright, trade secret or similar laws.

 

		(g)	“Work Product” shall mean any and all Inventions and possible Inventions relating
to the Business of the Company and which the Executive may make or conceive, alone or jointly with others, during his involvement
in any capacity with the Company, whether during or outside his regular working hours, except those Inventions made or conceived
by the Executive entirely on his own time that do not relate to the Business of the Company and do not derive from any equipment,
supplies, facilities, Confidential Information or other information, gained, directly or indirectly, from or through his involvement
in any capacity with the Company.

 

2.                              CONFIDENTIALITY

 

2.1                            Prior
Business Confidential Information. The Executive represents and warrants to the Company that the Executive has not brought
or used, and the Executive covenants and agrees that the Executive will not use or bring to the Company any confidential information
of any kind whatsoever of any prior party (the “Prior Business”) with whom the Executive was previously involved,
whether such involvement was as an employee, director or officer of that Prior Business, an investor in that Prior Business, a
partner in that Prior Business, a consultant to that Prior Business or other relationship to that Prior Business (the “Prior
Involvement”). The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain confidential information relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any and all legal obligations the Executive may have to such Prior Business. The Executive covenants
and agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer
as a result of any breach by the Executive of his obligations to such Prior Business in that regard.

 

2.2                             Basic Obligation of Confidentiality. The Executive hereby acknowledges and agrees that in the course of his involvement
with the Company, the Company may disclose to him or he may otherwise have access or be exposed to Confidential Information. The
Company hereby agrees to provide such access to the Executive and the Executive hereby agrees to receive and hold all Confidential
Information on the terms and conditions set out in this Agreement. Except as otherwise set out in this Agreement, the Executive
will keep strictly confidential all Confidential Information and all other information belonging to the Company that he acquires,
observes or is informed of, directly or indirectly, in connection with his involvement, in any capacity, with the Company both
during and after the term of his employment in any capacity with the Company.

 

    4

     

    

 

2.3                           Fiduciary
Capacity. The Executive will be and act toward the Company and its Affiliates as a fiduciary in respect of the Confidential
Information.

 

2.4                           Non-disclosure. Except with the prior written consent of the Company, the Executive will not at any time, either
during or after his involvement in any capacity with the Company;

 

		(a)	use or copy any Confidential Information or recollections thereof for any purpose other than the
performance of his duties for the benefit of the Company and its Affiliates;

 

		(b)	publish or disclose any Confidential Information or recollections thereof to any person other than
to employees of the Company and its Affiliates who have a need to know such Confidential Information in the performance of their
duties for the Company or its Affiliates;

 

		(c)	permit or cause any Confidential Information to be used, copied, published, disclosed, translated
or adapted except as otherwise expressly permitted by this Agreement; or

 

		(d)	permit or cause any Confidential Information to be stored off the premises of the Company, including
permitting or causing such Confidential Information to be stored in electronic format on personal computers, except in accordance
with written procedures of the Company, as amended from time to time in writing.

 

2.5                            Taking Precautions. The Executive will take all reasonable precautions necessary or prudent to prevent material in
his possession or control that contains or refers to Confidential Information from being discovered, used or copied by third parties.

 

2.6                            The Company’s Ownership of Confidential Information. As between the Executive and the Company, the Company
shall own all right, title and interest in and to the Confidential Information, whether or not created or developed by the Executive.

 

2.7                            Control of Confidential Information and Return of Information. All physical materials produced or prepared by the
Executive containing Confidential Information, including, without limitation, records, devices, computer files, data, notes, reports,
proposals, lists, correspondence, specifications, drawings, plans, materials, accounts, reports, financial statements, estimates
and all other materials prepared in the course of his responsibilities to or for the benefit of the Company or its Affiliates,
together with all copies thereof (in whatever medium recorded), shall belong to the Company, and the Executive will promptly turn
over to the Company’s possession every original and copy of any and all such items in his possession or control upon request
by the Company. If the material is such that it cannot reasonably be delivered, upon request from the Company, the Executive will
provide reasonable evidence that such materials have been destroyed, purged or erased.

 

    5

     

    

 

2.8                            Purpose of Use. The Executive agrees that he will use Confidential Information only for purposes authorized or directed
by the Company.

 

2.9                            Exemptions. The obligations of confidentiality set out in this Article 2 will not apply to any of the following:

 

		(a)	information that is already known to the Executive, though not due to a prior disclosure by the
Company or its Affiliates or by a person who obtained knowledge of the information, directly or indirectly, from the Company or
its Affiliates;

 

		(b)	information disclosed to the Executive by another person who is not obliged to maintain the confidentiality
of that information and who did not obtain knowledge of the information, directly or indirectly, from the Company or its Affiliates;

 

		(c)	information that is developed by the Executive independently of Confidential Information received
from the Company or its Affiliates and such independent development can be documented by the Executive;

 

		(d)	other particular information or material which the Company expressly exempts by written instrument
signed by the Company;

 

		(e)	information or material that is in the public domain through no fault of the Executive; and

 

		(f)	information required by operation of law, court order or government agency to be disclosed, provided
that:

 

		(i)	in the event that the Executive is required to disclose such information or material, upon becoming
aware of the obligation to disclose, the Executive will provide to the Company prompt written notice so that the Company may seek
a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement;

 

		(ii)	if the Company agrees that the disclosure is required by law, it will give the Executive written
authorization to disclose the information for the required purposes only;

 

		(iii)	if the Company does not agree that the disclosure is required by law, this Agreement will continue
to apply, except to the extent that a Court of competent jurisdiction orders otherwise; and

 

		(iv)	if a protective order or other remedy is not obtained or if compliance with this Agreement is waived,
the Executive will furnish only that portion of the Confidential Information that is legally required and will exercise all reasonable
efforts to obtain confidential treatment of such Confidential Information.

 

    6

     

    

3.                            ASSIGNMENT
OF INTELLECTUAL PROPERTY RIGHTS

 

3.1                          Notice
of Invention. The Executive agrees to promptly and fully inform the Company of all Work Product, whether or not patentable,
throughout the course of his involvement, in any capacity, with the Company and from which there is a reasonable basis to believe
that Intellectual Property may be derived therefrom, whether or not developed before or after execution of this Agreement. On
his ceasing to be employed by the Company for any reason whatsoever, the Executive will immediately deliver up to the Company
all Work Product.

 

3.2                          Assignment
of Rights. Subject only to the exceptions set out in Exhibit I attached to this Agreement, the Executive will assign,
and does hereby assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company’s
designee, all of his right, title and interest in and to all Work Product, including all Intellectual Property rights therein.
To the extent that the Executive retains or acquires legal title to any such Intellectual Property rights and interests, the Executive
hereby declares and confirms that such legal title is and will be held by him only as trustee and agent for the Company or the
Company’s designee. The Executive agrees that the Company’s rights hereunder shall attach to all Intellectual Property
rights in his Work Product, notwithstanding that it may be perfected or reduced to specific form after he has terminated his relationship
with the Company. The Executive further agrees that the Company’s rights hereunder are worldwide rights and are not limited
to Canada, but shall extend to every country of the world.

 

3.3                           Moral
Rights. Without limiting the foregoing, the Executive hereby irrevocably waives any and all moral rights arising under the
Copyright Act (Canada), as amended, or any successor legislation of similar force and effect or similar legislation in
other applicable jurisdictions or at common law that he may have with respect to all Work Product, and agrees never to assert
any moral rights which he may have in the Work Product, including, without limitation, the right to the integrity of the Work
Product, the right to be associated with the Work Product, the right to restrain or claim damages for any distortion, mutilation
or other modification or enhancement of the Work Product and the right to restrain the use or reproduction of the Work Product
in any context and in connection with any product, service, cause or institution, and the Executive further confirms that the
Company may use or alter any Work Product as the Company sees fits in its absolute discretion.

 

3.4                            Goodwill. The Executive hereby agrees that all goodwill he has established or may establish with clients, customers,
suppliers, principals, shareholders, investors, collaborators, strategic partners, licensees, contacts or prospects of the Company
relating to the Business of the Company (or of its partners, subsidiaries or affiliates), both before and after the Effective Date,
shall, as between the Executive and the Company, be and remain the property of the Company exclusively, for the Company to use,
alter, vary, adapt and exploit as the Company shall determine in its discretion.

 

3.5                            Assistance.
The Executive hereby agrees to reasonably assist the Company, at the Company’s request and expense, in:

 

		(a)	making patent applications for all Work Product, including instructions to lawyers and/or patent
agents as to the characteristics of the Work Product in sufficient detail to enable the preparation of a suitable patent specification,
to execute all formal documentation incidental to an application for letters patent and to execute assignment documents in favour
of the Company for such applications;

 

    7

     

    

 

		(b)	making applications for all other forms of Intellectual Property registration relating to all Work
Product;

 

		(c)	prosecuting and maintaining the patent applications and other Intellectual Property relating to
all Work Product; and

 

		(d)	registering, maintaining and enforcing the patents and other Intellectual Property registrations
relating to all Work Product.

 

If the Company is unable for any reason to secure the Executive’s
signature with respect to any Work Product including, without limitation, to apply for or to pursue any application for any patents
or copyright registrations covering such Work Product, then the Executive hereby irrevocably designates and appoints the Company
and its duly authorized officers and agents as his agent and attorney-in-fact, to act for and on his behalf and stead to execute
and file any papers, oaths and to do all other lawfully permitted acts with respect to such Work Product with the same legal force
and effect as if executed by him.

 

3.6                           Assistance with Proceedings. The Executive further agrees to reasonably assist the Company, at the Company’s
request and expense, in connection with any defence to an allegation of infringement of another person’s intellectual property
rights, claim of invalidity of another person’s intellectual property rights, opposition to, or intervention regarding, an
application for letters patent, copyright or trademark or other proceedings relating to Intellectual Property or applications for
registration thereof.

 

3.7                           Commercialization.
The Executive understands that the decision whether or not to commercialize or market any Work Product is within the Company’s
sole discretion and for the Company’s sole benefit and that no royalty or other consideration will be due or payable to
him as a result of the Company’s efforts to commercialize or market any such Work Product.

 

3.8                           Prior
Business Intellectual Property. The Executive represents and warrants to the Company that he has not brought or used,
and the Executive covenants and agrees that he will not use or bring to the Company any Intellectual Property of any kind
whatsoever of any Prior Business with whom the Executive had a Prior Involvement or any Intellectual Property directly owned
by the Executive. The Company and the Executive acknowledge and agree that the Company is not employing the Executive to
obtain Intellectual Property relating to any Prior Involvement and the Executive acknowledges that the Company has advised
the Executive to comply with any legal obligations the Executive may have to such Prior Business. The Executive covenants and
agrees to hold the Company harmless from any and all claims and damages of any kind whatsoever that the Company may suffer as
a result any breach by the Executive of his obligations to such Prior Business in that regard.

 

3.9                           Prior
Inventions. In order to have them excluded from this Agreement, the Executive has set forth on Exhibit I attached to
this Agreement a complete list of all Inventions for which a patent application has not yet been filed that he has, alone or jointly
with others, conceived, developed or reduced to practice prior to the execution of this Agreement to which he has any right, title
or interest, and which relate to the Business of the Company. If such list is blank or no such list is attached, the Executive
represents and warrants that there are no such prior Inventions.

 

    8

     

    

 

4.                             General

 

4.1                           Term.
Subject to Section 4.10, the term of this Agreement is from the Effective Date and terminates on the date that the Executive
is no longer working at or for the Company in any capacity.

 

4.2                           No
Conflicting Obligations. The Executive hereby represents and warrants that he has no agreements with or obligations to
any other person with respect to the matters covered by this Agreement or concerning the Confidential Information that are in
conflict with anything in this Agreement, except as disclosed in Exhibit I attached to this Agreement.

 

4.3                           Publicity. The Executive shall not, without the prior written consent of the Company, make or give any public announcements,
press releases or statements to the public or the press regarding any Work Product or any Confidential Information.

 

4.4                           Further
Assurances. The parties will execute and deliver to each other such further instruments and assurances and do such further
acts as may be required to give effect to this Agreement.

 

4.5                           Notices.
All notices and other communications that are required or permitted by this Agreement must be in writing and shall be hand
delivered or sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with
receipt confirmed in writing) to the parties at the addresses on page 1 of this Agreement. Any such notice shall be deemed to
have been received on the earlier of the date actually received or the date five (5) days after the same was posted or sent. Either
party may change its address or its facsimile number by giving the other party written notice, delivered in accordance with this
section.

 

4.6                           Equitable
Remedies. The Executive understands and acknowledges that if he breaches any of his obligations under this Agreement,
that breach may give rise to irreparable injury to the Company for which damages are an inadequate remedy. In the event of
any such breach by the Executive, in addition to all other remedies available to the Company at law or in equity, the Company
will be entitled as a matter of right to apply to a court of competent jurisdiction for such relief by way of restraining
order, injunction, decree or otherwise, as may be appropriate to ensure compliance with the provisions of this Agreement.

 

4.7                           Non-Waiver.
Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the other
party in default of this Agreement, irrespective of how long such failure continues, will not constitute a waiver by such
party of their rights hereunder or of the right to then or subsequently declare a default.

 

    9

     

    

 

4.8                           Severability.
In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in part, the
remaining provisions, or parts thereof, will be and remain in full force and effect.

 

4.9                           Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes any and all agreements, understandings, warranties or representations of any kind, written or oral,
express or implied, including any relating to the nature of the position or its duration, and each of the parties releases and
forever discharges the other of and from all manner of actions, causes of action, claim or demands whatsoever under or in respect
of any agreement.

 

4.10                         Survival. Notwithstanding the expiration or early termination of this Agreement, the provisions of Article 1, Article
2 (including the obligations of confidentiality and to return Confidential Information, which shall endure, with respect to each
item of Confidential Information, for so long as those items fall within the definition of Confidential Information), Sections
3.2, 3.3, 3.4, 3.5, 3.6 and 3.8 and Article 4 shall survive any expiration or early termination of this Agreement.

 

4.11                         Modification of Agreement. Any modification of this Agreement must be in writing and signed by both the
Company and the Executive or it will have no effect and will be void.

 

4.12                         Governing Law. This Agreement will be governed by and construed according to the laws of the Province of
British Columbia, Canada.

 

    10

     

    

 

4.13                         Independent Legal Advice. The Executive agrees that he has obtained or has had an opportunity to obtain independent
legal advice in connection with this Agreement, and further acknowledge that he has read, understands, and agrees to be bound by
all of the terms and conditions contained herein.

 

 

IN WITNESS WHEREOF this Agreement has been executed by the parties
hereto as of the date and year first above written.

 

 

	
         

        SIGNED, SEALED AND DELIVERED

        by Bruce Cousins in the
        presence of:

         
	
         

        )

        )

        )

        )

        )
	
         

         

         

         

         

        /s/ Bruce Cousins
	 
	Witness Signature

                                                                                

	
        )

        )
	Bruce Cousins	 
	Witness Name	
        )

        )
	 	 
	Witness Address	
        )

        )
	 	 
	

	
        )

        )
	 	 
	Witness Occupation	)	 	 

 

 

ARBUTUS BIOPHARMA CORPORATION

 

 

 

	Per:	/s/ Mark J. Murray	 
	 	Mark J. Murray	 

 

 

 

 

 

 

    11

     

    

EXHIBIT I

to Confidentiality and Assignment of Inventions Agreement

 

EXCLUSIONS FROM WORK PRODUCT

 

 

[To be completed as applicable]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    12

     

    

 

EXHIBIT B

 

GENERAL RELEASE LANGUAGE

 

The Executive agrees, for himself, his spouse, heirs, executor or
administrator, assigns, insurers, attorneys, and other persons or entities acting or purporting to act on his behalf (the “Executive’s
Parties”), to irrevocably and unconditionally release, acquit, and forever discharge the Company, its affiliates, subsidiaries,
directors, officers, employees, shareholders, partners, agents, representatives, predecessors, successors, assigns, insurers, attorneys,
benefit plans sponsored by the Company, and said plans’ fiduciaries, agents and trustees (the “Company’s Parties”),
from any and all actions, causes of action, suits, claims, obligations, liabilities, debts, demands, contentions, damages, judgments,
levies, and executions of any kind, whether in law or in equity, known or unknown, which the Executive’s Parties have, have
had, or may in the future claim to have against the Company’s Parties by reason of, arising out of, related to, or resulting
from the Executive’s employment with the Company or the termination of that employment. This release specifically includes
without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach of
contract, any claim arising under federal, state or local law prohibiting race, sex, age, religion, national origin, handicap,
disability, or other forms of discrimination, any claim arising under federal, state, or local law concerning employment practices,
and any claim relating to compensation or benefits. It is understood and agreed that the waiver of benefits and claims contained
in this section does not include a waiver of the right to payment of any vested, non-forfeitable benefits to which the Executive
or a beneficiary of the Executive may be entitled under the terms and provisions of any employee benefit plan of the company which
have accrued as of the Date of Termination, and does not include a waiver of the right to benefits and payment of consideration
to which the Executive may be entitled under this Agreement or any of the agreements contemplated by this Agreement (including
the indemnification agreement and the stock option agreement). The Executive acknowledges that he is entitled to only the severance
benefits and compensation set forth in this Agreement, and that all other claims for any other benefits or compensation are hereby
waived, except those expressly stated in the preceding sentence.

 

Executive agrees that he will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Company’s Parties or their products, employees, services, work
and/or employment.

 

The Company agrees that it will not make any derogatory statements,
either oral or written, or otherwise disparage any of the Executive’s Parties.

 

The Executive hereby acknowledges his understanding that under this
Agreement he is releasing any known or unknown claims he may have.

 

The Executive expressly waives and relinquishes all rights and benefits
under that section and any law of any jurisdiction of similar effect with respect to his release of claims.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]